Regardless, the difference in the role of GCNT1 between solid tumors and CLL underscores the importance of understanding the nature of the glycotope and counterreceptors serving as ligands for Siglecs. This evidence concerns the gene GCNT1 and B-cell chronic lymphocytic leukemia.